Investing.com - Stoke Therapeutics reported on Monday third quarter earnings that beat analysts' forecasts and revenue that topped expectations.
Stoke Therapeutics announced earnings per share of $-0.66 on revenue of $2.91M. Analysts polled by Investing.com anticipated EPS of $-0.68 on revenue of $2.72M.
Stoke Therapeutics shares are down 45% from the beginning of the year , still down 72.45% from its 52 week high of $33.06 set on Monday, November 22, 2021.
Stoke Therapeutics shares lost 27.06% in intra-day trade the report.
Stoke Therapeutics follows other major Healthcare sector earnings this month
Stoke Therapeutics's report follows an earnings beat by J&J on Tuesday, October 18, 2022, who reported EPS of $2.55 on revenue of $23.79B, compared to forecasts EPS of $2.48 on revenue of $23.36B.
Eli Lilly had beat expectations on Tuesday, November 1, 2022 with third quarter EPS of $1.98 on revenue of $6.94B, compared to forecast for EPS of $1.91 on revenue of $6.91B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar